were developed in China in the 1970s, are the only E. rhusiopathiae live attenuated vaccine strains used in China. 1, 11 The GC42 vaccine strain was generated via passage of field isolate C43-5 through cavies and chickens, and G4T10 was generated via passage of field isolate C43-5 through cavies and acriflavine treatment. 13 Field isolate C43-5 was collected in the 1950s, whereas isolate SE38 was collected in 2014.
Genomic DNA was obtained from the E. rhusiopathiae strains as previously described.
14 Polymerase chain reaction (PCR) amplification was performed in a 50-μL reaction mixture consisting of 50 ng of genomic DNA, 1 U of DNA polymerase a (the same as that used in the original report), 6 and 1.5 μL each of 20 μM SNP-specific primers 6 in a thermal cycler.
b The PCR conditions were: initial denaturation 665428V DIXXX10.1177/1040638716665428Rapid differentiation of Erysipelothrix rhusiopathiaeZhu et al. Our results demonstrated that the PCR assay can be used to differentiate Chinese live vaccine strains from field isolates (Fig. 1) . We observed 1 specific band for each of the Chinese live attenuated vaccine strains, whereas there was no specific band in the differentiation assay for either of the field isolates. Next, we sequenced the SNP sites of the 4 standard strains and/or isolates. The sequencing results (GenBank accession KT829597-KT829616; Table 1 ) further proved the validity of the PCR results. Only the 2 live attenuated vaccine strains had SNPs in the ERH_1398 locus (compared with Fujisawa strain), 6 the locus in which the differentiation assay amplified the specific bands. The differentiation assay results for the Chinese field isolates were identical to those for the Japanese field isolates-no band was produced. 6 However, each Chinese live attenuated vaccine strain had only 1 specific band, whereas the Japanese vaccine strain had 5 specific bands. 6 This difference reflects the different genetic backgrounds of the strains. Therefore, in countries with vaccine strains that differ from those used in Japan or China, an evaluation of this assay with relevant attenuated live vaccine strains and field isolates is required prior to any field application.
In the original report describing the assay, the authors speculated that PCR enzymes with excellent 3′ to 5′ exonuclease activity are a critical determinant of differentiation. 6 We compared the PCR using a DNA polymerase c with excellent 3′ to 5′ exonuclease activity with the PCR using a DNA polymerase d without 3′ to 5′ exonuclease activity. The results indicated a gain of specific bands in the ERH_0543, ERH_0636, and ERH_1398 loci from all strains in the assays using the DNA polymerase c with excellent 3′ to 5′ exonuclease activity ( Fig. 2A) . In contrast, the assay using the DNA polymerase d without 3′ to 5′ exonuclease activity yielded identical results (Fig. 2B) to those in the assay using DNA polymerase a (Fig. 1) . The 3′-terminal mismatched nucleotides of the primers were removed through the proofreading function in the PCR assay using an exo + polymerase 12 ; therefore, we speculate that the PCR amplifications with the exo + polymerase c are promoted in the ERH_0543, ERH_0636, and ERH_1398 loci. Thus, PCR enzymes without 3′ to 5′ exonuclease activity are recommended for the differentiation assay.
The use of monoclonal antibodies against Taq DNA polymerase in a hot-start PCR is an important method of improving PCR specificity. 3 Therefore, the performance of a PCR using an exo + polymerase e with an antibody that inhibits proofreading activity was also evaluated. We observed results (Fig. 3) that were identical to those in the assay using the DNA polymerase a (Fig. 1) . The DNA polymerase in the original report 6 was an exo + polymerase with an antibody that inhibits proofreading activity.
a From our results, we suggest that the critical determinant of successful differentiation is not the 3′ to 5′ exonuclease activity but, instead, is the antibody that inhibits proofreading activity. Therefore, if an exo + polymerase is used in the differentiation assay, it is recommended that the enzyme include an antibody that inhibits the enzyme's proofreading activity.
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